GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progen Co Ltd (XKRX:296160) » Definitions » Additional Paid-In Capital

Progen Co (XKRX:296160) Additional Paid-In Capital : ₩71,611.7 Mil(As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Progen Co Additional Paid-In Capital?


Progen Co's quarterly additional paid-in capital increased from . 20 (₩0.0 Mil) to Dec. 2023 (₩45,806.6 Mil) and increased from Dec. 2023 (₩45,806.6 Mil) to Dec. 2024 (₩71,611.7 Mil).

Progen Co's annual additional paid-in capital increased from . 20 (₩0.0 Mil) to Dec. 2023 (₩45,806.6 Mil) and increased from Dec. 2023 (₩45,806.6 Mil) to Dec. 2024 (₩71,611.7 Mil).

Progen Co Additional Paid-In Capital Historical Data

The historical data trend for Progen Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progen Co Additional Paid-In Capital Chart

Progen Co Annual Data
Trend Dec23 Dec24
Additional Paid-In Capital
45,806.60 71,611.65

Progen Co Semi-Annual Data
Dec23 Dec24
Additional Paid-In Capital 45,806.60 71,611.65

Progen Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Progen Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Progen Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Progen Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progen Co Ltd (XKRX:296160) » Definitions » Additional Paid-In Capital
Comparable Companies
XKRX:049960 XKRX:261780 XKRX:166480 XKRX:388870 XKRX:378800 XKRX:314130 XKRX:348150 XKRX:067370 XKRX:168330 XKRX:185490 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
172 Magokjungang-ro, 7th Floor, Bio Innovation Park, Gangseo-gu, Seoul, KOR
Website
http://www.progen.co.kr
Progen Co Ltd is an R&D focused biopharmaceutical development venture. It is engaged in developing metabolic disease treatments, immune disease treatments, and immune anti cancer drugs using its immunology based drug development know how, and is focusing on developing inventive drugs through domestic and international open innovation.

Progen Co Headlines

No Headlines